Oncothyreon (ONTY) Bullish Stance Reiterated at Cowen as Efficacy Continues To Impress

Cowen analyst Boris Peaker reiterated an Outperform rating on Oncothyreon (NASDAQ: ONTY) provided a further update on its Phase 1b trials in third line HER2+ metastatic breast cancer at ASCO. The analyst notes efficacy continues to impress and '380 will advance into Phase II.

Peaker commented, "ONTY provided a further update on its Phase 1b trials in third line HER2+ metastatic breast cancer. Data continues to show encouraging trend, with 52% ORR in 27 evaluable patients and 33% stable disease. In CNS mets group, ORR was 36%. most importantly, the drug was well tolerated without grade 3 diarrhea. Phase 2 studies are being planned."

For an analyst ratings summary and ratings history on Oncothyreon click here. For more ratings news on Oncothyreon click here.

Shares of Oncothyreon closed at $3.42 yesterday.

You May Also Be Interested In

• Knight Transportation (KNX) PT Lowered to $52 at TD Cowen
• Citi Reiterates Buy Rating on Abbott Labs (ABT)
• Itau BBA Reiterates Outperform Rating on WEG S.A. (WEGE3:BZ) (WEGZY)